Maud Brandely

844 total citations
19 papers, 635 citations indexed

About

Maud Brandely is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, Maud Brandely has authored 19 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 5 papers in Hematology and 4 papers in Oncology. Recurrent topics in Maud Brandely's work include Immune Cell Function and Interaction (7 papers), Immunotherapy and Immune Responses (4 papers) and Acute Myeloid Leukemia Research (3 papers). Maud Brandely is often cited by papers focused on Immune Cell Function and Interaction (7 papers), Immunotherapy and Immune Responses (4 papers) and Acute Myeloid Leukemia Research (3 papers). Maud Brandely collaborates with scholars based in France, United States and Italy. Maud Brandely's co-authors include Warren D. Johnson, R. Falcoff, D Pedral-Sampaio, E Falcoff, John L. Ho, Edgar M. Carvalho, Rodolfo S. Teixeira, Manoel Barral‐Netto, Heonir Rocha and Luciana da Silva and has published in prestigious journals such as New England Journal of Medicine, Hepatology and Cancer.

In The Last Decade

Maud Brandely

18 papers receiving 597 citations

Peers

Maud Brandely
H Festenstein United Kingdom
Guido Hegasy Germany
Patricia Paredes-Casillas Mexico
Xilai Ding China
Christine Y. Louie United States
S Tanikawa Japan
V Suvatte Thailand
Mathieu Dupont France
Giampiero D’Offizi Italy
G. Loss United States
H Festenstein United Kingdom
Maud Brandely
Citations per year, relative to Maud Brandely Maud Brandely (= 1×) peers H Festenstein

Countries citing papers authored by Maud Brandely

Since Specialization
Citations

This map shows the geographic impact of Maud Brandely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maud Brandely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maud Brandely more than expected).

Fields of papers citing papers by Maud Brandely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maud Brandely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maud Brandely. The network helps show where Maud Brandely may publish in the future.

Co-authorship network of co-authors of Maud Brandely

This figure shows the co-authorship network connecting the top 25 collaborators of Maud Brandely. A scholar is included among the top collaborators of Maud Brandely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maud Brandely. Maud Brandely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Block, Matthew S., Jean‐Pierre Delord, Christian H. Ottensmeier, et al.. (2022). Abstract CT182: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients. Cancer Research. 82(12_Supplement). CT182–CT182.
2.
Zoulim, Fabien, François Habersetzer, Martin F. Sprinzl, et al.. (2019). Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Human Vaccines & Immunotherapeutics. 16(2). 388–399. 66 indexed citations
3.
Kitzen, Jos, C. Puozzo, Maja J. De Jonge, Maud Brandely, & Jaap Verweij. (2009). Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study. European Journal of Cancer. 46(2). 266–269. 7 indexed citations
4.
Campone, Mario, et al.. (2008). Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 63(5). 937–943. 7 indexed citations
5.
Vey, Norbert, Didier Blaise, Marina Lafage, et al.. (1999). Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients. Journal of Immunotherapy. 22(2). 175–181. 9 indexed citations
6.
Vey, Norbert, Patrice Viens, Anne-Marie Stoppa, et al.. (1998). A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia. Leukemia & lymphoma. 31(3-4). 343–349. 45 indexed citations
7.
8.
Vey, Norbert, Didier Blaise, Pierre Tiberghien, et al.. (1996). A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas. Leukemia & lymphoma. 21(1-2). 107–114. 14 indexed citations
9.
Mathiot, Claire, A Portier, Maud Brandely, et al.. (1994). Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2. Cancer Immunology Immunotherapy. 39(1). 53–58. 18 indexed citations
10.
Wolkenstein, P., O. Chosidow, Janine Wechsler, et al.. (1993). Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. Journal of the American Academy of Dermatology. 28(1). 66–70. 21 indexed citations
11.
Astoul, Philippe, J. R. Viallat, J. C. Laurent, Maud Brandely, & C Boutin. (1993). Intrapleural Recombinant IL-2 in Passive Immunotherapy for Malignant Pleural Effusion. CHEST Journal. 103(1). 209–213. 68 indexed citations
12.
Tiberghien, Pierre, E Racadot, Marie Deschaseaux, et al.. (1992). Interleukin-2-induced increase of a monoclonal b-cell lymphocytosis. A novel In vivo interleukin-2 effect?. Cancer. 69(10). 2583–2588. 2 indexed citations
13.
14.
Marcellin, Patrick, Marie‐Anne Loriot, Nathalie Boyer, et al.. (1990). Recombinant Human γ–Interferon in Patients With Chronic Active Hepatitis B: Pharmacokinetics, Tolerance and Biological Effects. Hepatology. 12(1). 155–158. 35 indexed citations
15.
Boué, François, M. Spielmann, Thierry Le Chevalier, et al.. (1990). A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients. Cancer Immunology Immunotherapy. 32(1). 67–70. 11 indexed citations
16.
Badaró, Roberto, E Falcoff, F. Badaró, et al.. (1990). Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma. New England Journal of Medicine. 322(1). 16–21. 245 indexed citations
17.
Tolédano, Michel B., Claire Mathiot, Jean Michon, et al.. (1989). Interferon-γ (IFN-γ) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity — IFN-γ-induced suppressive activity. Cancer Immunology Immunotherapy. 30(1). 57–64. 15 indexed citations
18.
Motta, Iris, Maud Brandely, Paolo Truffa‐Bachi, Bruno Hurtrel, & Philippe Lagrange. (1985). Effects of Suramin on the immune responses to sheep red blood cells in mice. Cellular Immunology. 93(2). 292–302. 5 indexed citations
19.
Brandely, Maud, Philippe Lagrange, Bruno Hurtrel, Iris Motta, & Paolo Truffa‐Bachi. (1985). Effects of Suramin on the immune responses to sheep red blood cells in mice. Cellular Immunology. 93(2). 280–291. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H Festenstein Breakdown of academic impact, for papers by Guido Hegasy Breakdown of academic impact, for papers by Patricia Paredes-Casillas Breakdown of academic impact, for papers by Xilai Ding Breakdown of academic impact, for papers by Christine Y. Louie Breakdown of academic impact, for papers by S Tanikawa Breakdown of academic impact, for papers by V Suvatte Breakdown of academic impact, for papers by Mathieu Dupont Breakdown of academic impact, for papers by Giampiero D’Offizi Breakdown of academic impact, for papers by G. Loss
Rankless by CCL
2026